Pfizer and BioNTech Reach Agreement with COVAX for Advance Purchase of Vaccine to Help Combat COVID-19
January 22, 2021 12:00 ET
|
BioNTech SE
Initial agreement provides up to 40 million doses to COVAX in 2021First deliveries are expected to take place in Q1 2021 subject to the execution of supply agreements under the COVAX Facility...
Pfizer-BioNTech-COVID-19-Impfstoff induziert im Zellmodell Antikörper, die Pseudoviren mit dem Spike-Protein der U.K.-SARS-CoV-2-Variante neutralisieren
January 20, 2021 07:50 ET
|
BioNTech SE
NEW YORK, USA und MAINZ, Deutschland, 20. Januar 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) und BioNTech SE (Nasdaq: BNTX) gaben heute die Ergebnisse einer in-vitro-Studie bekannt, die das...
Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture
January 20, 2021 07:50 ET
|
BioNTech SE
New York and Mainz, Germany, January 20, 2021 — Today, Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced results from an in vitro study that provides additional data on the capability...
Pfizer-BioNTech COVID-19-Impfstoff löst in vitro neutralisierende Antikörperantwort gegen SARS-CoV-2 mit einer Mutation aus, die mit einer schnellen Übertragung assoziiert wird
January 08, 2021 05:45 ET
|
BioNTech SE
New York und Mainz, Deutschland 08. Januar 2021 — Pfizer Inc. (NYSE: PFE) und BioNTech SE (Nasdaq: BNTX) gaben heute Ergebnisse einer in vitro-Studie bekannt, die zeigen, dass Personen, die den...
An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission
January 08, 2021 05:45 ET
|
BioNTech SE
New York and Mainz, Germany, January 8, 2021 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an in vitro study conducted by Pfizer and the University of Texas...
BioNTech veröffentlicht Daten zu neuartigem mRNA-Impfstoffansatz gegen Autoimmunkrankheiten in Science
January 07, 2021 14:15 ET
|
BioNTech SE
Gemeinsame Studie von BioNTech, TRON und der Universitätsmedizin sowie dem Forschungszentrum für Immuntherapie der Johannes Gutenberg-Universität Mainz untersucht neuartigen entzündungshemmenden...
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
January 07, 2021 14:15 ET
|
BioNTech SE
Collaborative study of BioNTech with TRON and the University Medical Center and Research Center for Immunotherapy at Johannes Gutenberg University of Mainz introduces novel non-inflammatory mRNA...
BioNTech präsentiert auf der 39. Annual J.P. Morgan Healthcare Conference
January 05, 2021 06:00 ET
|
BioNTech SE
MAINZ, Deutschland, 5. Januar 2021 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, „BioNTech” oder „das Unternehmen”) gab heute bekannt, dass CEO und Mitgründer Prof. Dr. Ugur Sahin das Unternehmen...
BioNTech to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 06:00 ET
|
BioNTech SE
MAINZ, GERMANY, January 5, 2021 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO and Co-founder Ugur Sahin, M.D., will present a corporate overview...
Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®
December 29, 2020 13:10 ET
|
BioNTech SE
European Union orders 100 million additional doses of COMIRNATY® bringing total doses to 300 million for 27 EU member states All 300 million doses expected to be delivered in 2020 and 2021 ...